For further details see:
KaliVir Immunotherapeutics inks agreement with Astellas for development and commercialization of VET2-L2home / stock / alpmy / alpmy news
For further details see:
KaliVir Immunotherapeutics inks agreement with Astellas for development and commercialization of VET2-L2Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Astellas Pharma Inc. ADR Company Name:
ALPMY Stock Symbol:
OTCMKTS Market:
Astellas Receives Positive CHMP Opinion for Zolbetuximab in Combination with Chemotherapy for Treatment of Advanced Gastric and Gastroesophageal Junction Cancer PR Newswire - If approved by the European Commission, zolbetuximab would become the first and only CLDN18.2-targeted...
Astellas Receives Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer PR Newswire - If approved, enfortumab vedotin in combination with pembrolizumab ...
Astellas and Graduate School of Medicine / Faculty of Medicine, Osaka University Enter into Research Collaboration to Develop Pluripotent Stem Cell-Derived Cartilage Organoid Cell Therapy PR Newswire - Collaborative Research on Innovative Cartilage Organoid Cell Therapy for In...